JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain
/PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has...
Source: prnewswire.com